NeuroAI NEUROAINEUROAI.SITE
China AI, reported clearly
1,300+ verified stories on models, robotics, BCI and the business of AI.
Browse stories
ESC

Shanghai says it now hosts 120+ brain-computer interface companies, and the world's first approved invasive BCI implant has done 12 commercial surgeries there

At a briefing ahead of the Pujiang Innovation Forum BCI conference, Shanghai officials said the city hosts over a third of China's BCI companies, raised 4 billion yuan this year, and that BoRuiKang's NEO implant — covered by local insurance up to 30% — has completed 12 commercial placements.

2026-11-18 · 1025 words · NeuroAI
Shanghai says it now hosts 120+ brain-computer interface companies, and the world's first approved invasive BCI implant has done 12 commercial surgeries there

Twelve patients are walking around with the world's first approved invasive brain-computer interface implant, a device cleared in March as a Class III medical device and prescribed for the first time at a Shanghai hospital in July. All of it happened in one city, and city officials have started counting.

At a 12 November media briefing for the Pujiang Innovation Forum 2026 Brain-Computer Interface Conference, Shanghai's science and technology commission gave an accounting of what the city's BCI (脑机接口) sector now looks like — and the numbers put a scale on a field most people still associate with laboratory trials.

Key takeaways

  • Shanghai hosts more than 120 brain-computer interface companies, roughly one-third of China's total, said Qu Wei (屈炜), deputy director of the Shanghai Municipal Science and Technology Commission, at the briefing.
  • The city's BCI companies raised more than 4 billion yuan (about US$560 million) in financing this year, and three companies are pursuing IPOs (Xinhua Finance, 13 November 2026).
  • BoRuiKang's (博睿康) NEO system became the world's first approved invasive BCI medical device when it received Class III registration on 13 March; the first prescription was written on 13 July at Huashan Hospital, with the world's first commercial implant surgery completed the same day.
  • NEO has completed 12 commercial implants and is covered by Shanghai's Huibao (沪惠保) supplementary insurance at up to 30% reimbursement.
  • Hongbo, chief scientist at the Lingang Laboratory, put the national picture at roughly 120 patients with implants in place for more than a month, and more than 20 hospitals nationwide running BCI clinics or wards.

What "a third of a national sector" means

Qu Wei's briefing framed Shanghai as the core carrier of a national strategy: China's 15th Five-Year Plan outline, published earlier this year, listed brain-computer interfaces among the future industries it wants to cultivate. Shanghai issued its own cultivation plan in January 2025 — the first provincial-level BCI action plan in China — and opened the "Brain-Intelligence Realm" (脑智天地) cluster in Minhang District in June 2025 as the country's first dedicated BCI industry zone.

The cluster numbers give the sector a physical address: Minhang District has recruited 78 BCI companies, about 65% of the city's total, with 65 located in the cluster itself. A district-level BCI fund of 500 million yuan (about US$69 million) co-founded with private capital has invested in nine projects. The district's pipeline counts more than 50 products in development, several of them in clinical trials or Class III registration stages.

Beyond the cluster, the briefing detailed shared platforms that lower the cost of doing BCI work in Shanghai: a concept-validation platform with 16 projects approved and 4 spun into companies, an incubator at 85% occupancy with 26 tenants, a research ward that has handled 203 clinical referrals, and an intracranial EEG database holding 1,026 valid case records.

From first approval to paying patients

The clinical chain is what distinguishes Shanghai's numbers from cluster-building elsewhere. NEO, developed by BoRuiKang, compensates for hand-motor function in patients with limb paralysis caused by cervical spinal-cord injury. In a 32-patient clinical follow-up, 81.3% of subjects showed functional recovery at twelve months post-surgery, with hand-grip function reaching clinically significant levels.

The commercial steps followed in sequence: regulatory approval in March, the first prescription at Huashan Hospital on 13 July, a commercial implant the same day, and now 12 commercial placements. The payment piece may matter as much as the clinical one — inclusion in Huibao, Shanghai's government-guided supplementary medical insurance, at up to 30% reimbursement makes NEO apparently the first invasive BCI implant anywhere with a routine reimbursement pathway, rather than a trial-funded one.

Other programmes named at the briefing flesh out the pipeline: Beijing's "Brain No. 1" (北脑一号) semi-invasive system has completed more than 40 human implants with registration trials fully enrolled, targeting a Class III filing in 2027; NeuroXess (脑虎科技) started a GCP registration trial at Huashan Hospital in July for its fully implanted, fully wireless intracortical system; StairMed (阶梯医疗) has completed 42 fully invasive long-term implants, described as the most of any fully invasive BCI company globally; and Zhiran Medical began a multi-centre trial in May across 11 medical institutions.

Hongbo summarised the year with two labels: the "first year of clinical application" (临床应用元年) and the "first year of the data ecosystem" (数据生态元年). The data side is now getting national infrastructure — a national EEG data centre, led by the Lingang Laboratory with Tsinghua and Huashan Hospital, is being organised on a "one centre, two core nodes, national network" architecture, with its formation formally announced at the conference in December.

Honest limitations

Nearly every figure here comes from a government-organised media briefing — the counts of companies, financing and IPO candidates are official statements relayed by Xinhua Finance, China Youth Daily and district government channels, not independently audited numbers. "Company" in the 120+ count is undefined, and jurisdictions define it differently; some entities may be research groups incorporated as firms. The 81.3% functional-recovery figure is a company-sponsored trial result reported at a briefing, and the 12-implant count comes from the same source. The Huibao reimbursement is capped ("up to 30%") and applies to Shanghai policyholders. None of the three IPO candidates was named at the briefing, so their status cannot be verified against filings. And NEO remains a device for one indication — cervical spinal-cord injury — so its commercial experience, however genuine, is narrow.

What readers can do now

  • If you follow BCI regulation, note the sequence Shanghai demonstrated — device approval, prescription, insurance inclusion — as a template other jurisdictions will be measured against; the December conference is where the national EEG data centre structure will be detailed.
  • If you invest in the space, the three unnamed IPO candidates give you a shortlist problem: watch Minhang-cluster companies in registration-trial stages for filing disclosures.
  • If you work in neuro-rehabilitation, the 30% reimbursement cap on Huibao is the first concrete number for patient-side cost sharing on an invasive implant, and a data point for designing coverage elsewhere.
  • If you build BCI tooling, the platform inventory at the briefing — shared wards, EEG databases, concept-validation funding — describes infrastructure you can apply to access rather than build.

Related coverage

Cite this article

NeuroAI (脑机网), "Shanghai says it now hosts 120+ brain-computer interface companies, and the world's first approved invasive BCI implant has done 12 commercial surgeries there," 18 November 2026, https://neuroai.site/a/na-corp-shanghai-bci-cluster

Machine-readable: BibTeX · RIS · JSON · Markdown

More in “Companies & Stack” → · Back to home · Markdown version

China AI, reported clearly
1,300+ verified stories on models, robotics, BCI and the business of AI.
Browse stories